These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
- Summit Therapeutics (NASDAQ:SMMT) shares fell 14.37% last week after Citigroup downgraded the stock from Buy to Neutral but raised its price target from $19 to $23.
- MakeMyTrip Limited (NASDAQ:MMYT) stock plummeted 12.46%.
- Medpace Holdings, Inc. (NASDAQ:MEDP) stock fell 9.37% after Jefferies downgraded the stock from Buy to Hold and cut its price target from $415 to $345.
- Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock lost 8.94% last week after Leerink Partners downgraded it from Outperform to Market Perform and lowered its price target from $1,175 to $1,077.
- Global Payments Inc. (NYSE:GPN) shares dived 8.74% after the company guided FY25 EPS growth below estimates, and multiple firms downgraded the stock and cut their respective price targets.
- Affirm Holdings Inc. (NASDAQ:AFRM) stock lost 8.39% last week. There was no company-specific news to justify the price loss.
- Super Micro Computer, Inc. (NASDAQ:SMCI) shares dipped 8.21% following a report indicating the company is being probed by the Department of Justice following an August short report from Hindenburg Research.
- TechnipFMC plc (NYSE:FTI) stock fell 6.10% amid reports suggesting Saudi Arabia may raise crude oil output.
- First Citizens BancShares, Inc. (NASDAQ:FCNCA) stock lost 6.09% last week after Wedbush analyst downgraded the stock from Outperform to Neutral and lowered the price target from $2,450 to $2,150.
- ServiceNow, Inc. (NYSE:NOW) stock fell 5.93% from pressure following the DOJ’s Carahsoft investigation.
Also Read:
Photo via Company
REGNRegeneron Pharmaceuticals Inc
$699.77-0.50%
SMCISuper Micro Computer Inc
$35.08-0.83%
AFRMAffirm Holdings Inc
$69.742.39%
FCNCAFirst Citizens BancShares Inc
$1981.960.60%
FTITechnipFMC PLC
$46.111.72%
KNTKKinetik Holdings Inc
$37.661.95%
MEDPMedpace Holdings Inc
$548.36-0.15%
MMYTMakeMyTrip Ltd
$71.852.86%
NOWServiceNow Inc
$855.750.26%
SMMTSummit Therapeutics Inc
$17.74-4.75%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
